Showing 431-440 of 1321 results for "".
- Analysis Uncovers Health Economic Data for H.P. Acthar® Gel in Dermatomyositis and Polymyositishttps://practicaldermatology.com/news/analysis-uncover-health-economic-data-for-hp-acthar-gel-in-dermatomyositis-and-polymyositis/2458519/Results from two retrospective analyses sponsored by Mallinckrodt plc show that use of the company’s H.P. Acthar® Gel (repository corticotropin injection) offers a cost-effec
- Galderma's Cetaphil® Launches Limited-edition Product Display Honoring Camp Wonderhttps://practicaldermatology.com/news/galdermas-cetaphil-launches-limited-edition-product-display-honoring-camp-wonder/2458529/Galderma Laboratories is unveiling a limited-edition product display in partnership with the Children's Skin Disease Foundation (CSDF) and Camp Wonder, an initiative of the CSDF. As part of a fi
- New Psoriasis Drug Taltz Shows Benefit Through 60 Weekshttps://practicaldermatology.com/news/new-psoriasis-drug-taltz-shows-benefit-through-60-weeks/2458536/Three new studies demonstrate the efficacy and safety of Eli Lilly's Taltz® (ixekizumab) through 60 weeks among patients with moderate-to-severe plaque psoriasis. The findings appear in the
- Allergan's TEFLARO® OK'd for Pediatric Patientshttps://practicaldermatology.com/news/allergans-teflaro-oked-for-pediatric-patients/2458547/Allergan’s TEFLARO® (ceftaroline fosamil) is now indicated for pediatric patients, making it the first branded IV antibiotic approved for this population in more than a decade. The U.S. Food and Drug Administration (FDA) appr
- Is Eli Lilly's Taltz the Next Blockbuster Drug for Psoriasis?https://practicaldermatology.com/news/is-eli-lillys-taltz-the-next-blockbuster-drug-for-psoriasis/2458569/Eli Lilly’s new psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its efficacy and good safety profile, according to an analyst at GlobalData.
- Valeant Announces Nominees For Election To Board Of Directorshttps://practicaldermatology.com/news/valeant-announces-nominees-for-election-to-board-of-directors/2458585/Valeant Pharmaceuticals International, Inc. announced the nominees for election to its Board of Directors at the 2016 Annual Meeting of Shareholders on June 14, 2016. As previoulsy announced, Joseph C. Papa has been named Valeant's
- Johnson & Johnson Consumer to Acquire NeoStratahttps://practicaldermatology.com/news/johnson-johnson-consumer-to-to-acquire-neostrata/2458589/Johnson & Johnson Consumer, Inc. has entered into a definitive agreement to acquire NeoStrata Company, Inc. The acquisition will include NeoStrata's affiliates and parent company TriStrata, Incorporated, a privately-held compan
- ASA Lauds Three Honorees at Spring Galahttps://practicaldermatology.com/news/asa-lauds-three-honorees-at-spring-gala/2458602/The American Skin Association (ASA) honored Yale Educator Irwin M. Braverman, MD, Melanoma Researcher John M. Kirkwood MD and Nestlé’s SHIELD program at their Spring gala in New
- FDA Clears Venus Versa for 20-Plus Common Clinical Indicationshttps://practicaldermatology.com/news/fda-clears-venus-versatm-for-20-plus-common-clinical-indications/2458632/The U.S. Food and Drug Administration cleared Venus Concept’s Venus Versa™ system for skin rejuvenation, hair removal, facial wrinkles and rhytides, skin resurfacing, pigmented and vascular lesions, and acne vulgaris.
- APP® Membership Now Has More Rewards: Three Syneron Candela Platformshttps://practicaldermatology.com/news/app-membership-now-has-more-rewards-three-syneron-candela-platforms/2458655/Syneron Medical Ltd. and Allergan plc are joining forces to offer three of Syneron Candela's body sculpting and skincare platforms to members of Allergan Partner Privileges® (APP®</